<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>2</volume><submitter>Othman RT</submitter><pubmed_abstract>&lt;h4>Introduction&lt;/h4>Medulloblastoma (MB) is the most common malignant paediatric brain tumour. Recurrence and progression of disease occurs in 15-20% of standard risk and 30-40% of high risk patients. We analysed whether circumvention of chemoresistance pathways (drug export, DNA repair and apoptotic inhibition) can restore chemotherapeutic efficacy in a panel of MB cell lines.&lt;h4>Results&lt;/h4>We demonstrate, by immunohistochemistry in patient tissue microarrays, that ABCB1 is expressed in 43% of tumours and is significantly associated with high-risk. We show that ABCB1, O6-methylguanine-DNA-methyltransferase (MGMT) and BCL2 family members are differentially expressed (by quantitative reverse transcription polymerase chain reaction, Western blotting and flow cytometry) in MB cell lines. Ba</pubmed_abstract><journal>Acta neuropathologica communications</journal><pagination>57</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4229867</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Overcoming multiple drug resistance mechanisms in medulloblastoma.</pubmed_title><pmcid>PMC4229867</pmcid><pubmed_authors>Kimishi I</pubmed_authors><pubmed_authors>Bradshaw TD</pubmed_authors><pubmed_authors>Othman RT</pubmed_authors><pubmed_authors>Kerr ID</pubmed_authors><pubmed_authors>Grundy RG</pubmed_authors><pubmed_authors>Pfister SM</pubmed_authors><pubmed_authors>Storer LC</pubmed_authors><pubmed_authors>Korshunov A</pubmed_authors><pubmed_authors>Coyle B</pubmed_authors></additional><is_claimable>false</is_claimable><name>Overcoming multiple drug resistance mechanisms in medulloblastoma.</name><description>&lt;h4>Introduction&lt;/h4>Medulloblastoma (MB) is the most common malignant paediatric brain tumour. Recurrence and progression of disease occurs in 15-20% of standard risk and 30-40% of high risk patients. We analysed whether circumvention of chemoresistance pathways (drug export, DNA repair and apoptotic inhibition) can restore chemotherapeutic efficacy in a panel of MB cell lines.&lt;h4>Results&lt;/h4>We demonstrate, by immunohistochemistry in patient tissue microarrays, that ABCB1 is expressed in 43% of tumours and is significantly associated with high-risk. We show that ABCB1, O6-methylguanine-DNA-methyltransferase (MGMT) and BCL2 family members are differentially expressed (by quantitative reverse transcription polymerase chain reaction, Western blotting and flow cytometry) in MB cell lines. Ba</description><dates><release>2014-01-01T00:00:00Z</release><publication>2014 May</publication><modification>2025-04-05T00:22:23.447Z</modification><creation>2019-03-27T01:39:28Z</creation></dates><accession>S-EPMC4229867</accession><cross_references><pubmed>24887326</pubmed><doi>10.1186/2051-5960-2-57</doi></cross_references></HashMap>